JUPITER

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

Top

Rautio N, Jokelainen J, Oksa H, et al. Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open. 2012;2(5). pii: e001472. doi: 10.1136/bmjopen-2012-001472. Treatment with statins has been linked to an increased risk for type 2 diabetes in several post-hoc evaluations of previous completed trials, leading to controversy regarding the risk/benefit profile of statin therapy for primary prevention in patients who are at low risk for developing cardiovascular (CV) events.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Top

Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. Sattar and colleagues conducted a meta-analysis to assess whether a relationship between statin use and development of diabetes exists.

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER

Top

Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US. J Am Coll Cardiol. 2009;53(11):931-935. We assessed the prevalence of low-density lipoprotein-cholesterol (LDL-C) <130 mg/dl with elevated high-sensitivity C-reactive protein (hsCRP) in the National Health And Nutrition Examination Survey (NHANES), weighted to be representative of the general U.S. population.